{"id":"capecitabine-pill","safety":{"commonSideEffects":[{"rate":"60","effect":"Hand-foot skin reaction"},{"rate":"47","effect":"Diarrhea"},{"rate":"37","effect":"Nausea"},{"rate":"16","effect":"Vomiting"},{"rate":"42","effect":"Fatigue"},{"rate":"26","effect":"Neutropenia"},{"rate":"5","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tissue-level enzymatic conversion to 5-fluorouracil (5-FU). Once activated, it inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This mechanism preferentially affects rapidly dividing cancer cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:54.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT06105684","phase":"PHASE2","title":"Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-14","conditions":"Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT00680901","phase":"PHASE3","title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06-04","conditions":"Neoplasms, Gastrointestinal Tract","enrollment":545},{"nctId":"NCT05086731","phase":"NA","title":"Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-10-22","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":33},{"nctId":"NCT06313983","phase":"PHASE3","title":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-01-08","conditions":"Breast Cancer","enrollment":339},{"nctId":"NCT05212454","phase":"PHASE3","title":"Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-15","conditions":"Breast Cancer, Chemotherapy Effect","enrollment":400},{"nctId":"NCT03299660","phase":"PHASE2","title":"Avelumab With Chemoradiation in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2018-04-30","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":"Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell","enrollment":8},{"nctId":"NCT02000882","phase":"PHASE2","title":"STAR Cape+BKM120 MBC With Brain Met","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2014-05-29","conditions":"Brain Metastases, Breast Cancer, Metastatic Breast Cancer","enrollment":10},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00916578","phase":"PHASE2","title":"Xeloda (Capecitabine) and External Beam Radiation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-05","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT02767752","phase":"PHASE2","title":"Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer","status":"TERMINATED","sponsor":"Herlev Hospital","startDate":"2016-11","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT02664103","phase":"PHASE2","title":"Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-23","conditions":"Breast Cancer Metastatic","enrollment":2},{"nctId":"NCT03389659","phase":"PHASE3","title":"XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02","conditions":"Vitamin D3","enrollment":750},{"nctId":"NCT01754623","phase":"PHASE2","title":"GTX-RT in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT01584544","phase":"PHASE1","title":"Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-01","conditions":"Rectal Neoplasms","enrollment":24},{"nctId":"NCT01268943","phase":"PHASE1","title":"Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2010-11","conditions":"Rectal Neoplasms","enrollment":18},{"nctId":"NCT00493636","phase":"PHASE2","title":"1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2007-06","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT01097018","phase":"PHASE3","title":"Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2010-04","conditions":"Colorectal Cancer","enrollment":468}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeloda"],"phase":"phase_2","status":"active","brandName":"Capecitabine Pill","genericName":"Capecitabine Pill","companyName":"Peter MacCallum Cancer Centre, Australia","companyId":"peter-maccallum-cancer-centre-australia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}